* Directors / Signatories / KMP / Principals

AUROBINDO PHARMA LTD

Company Status: Active As on: 06-Aug-2019

D&B Summary

Paid-up Capital(INR)
585,915,609
Authorised Capital(INR)
760,000,000
Total Charges(INR)
Open Charges(INR)
D&B Reports
Compliance Report
INR 14000.00 /-
Report Status : Available
Financial Year : 2020
Basic Report
INR 6000.00 /-
Report Status : Available
Financial Year : 2020
Quick Check Report
INR 2500.00 /-
Report Status : Available
Financial Year : 2020
Sectoral Risk Outlook (Industry Report)
Sectoral Risk Outlook (Industry Report) Status : Unavailable
Financial Year : NA
Business of interest
Low High
No. of search on company
16
80% Complete
News

Aurobindo Pharma Q3 net up 17% at ₹836 crore - BusinessLine


Aurobindo Pharma Ltd up for five straight sessions - Business Standard


Aurobindo Pharma Q3 Results: Net Profit Jumps Fourfold On One-Offs; Shares Drop - BloombergQuint


Buy Aurobindo Pharma, target price Rs 1100: Motilal Oswal - Economic Times


Aurobindo Pharma Ltd Board approves interim dividend of Rs. 1.50 for FY21 - Equity Bulls


Aurobindo Pharma receives USFDA Approval for Droxidopa Capsules - Equity Bulls


Aurobindo Pharma Limited inks agreement to acquire 26% ownerships in two solar power generating companies - Equity Bulls


Q3FY21 Result Update - Aurobindo Pharma - ICICI Direct - Equity Bulls


Alprazolam Tablets Market - Aurobindo Pharma Ltd., Mylan N.V., Par Pharmaceuticals, Pfizer Inc., Taj Pharmaceu - openPR


Active Pharmaceutical Ingredients (API) Market Witness Robust Growth | AbbVie Inc.,Astrazeneca,Aurobindo Pharma Ltd.,BASF – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper


Edited Transcript of ARBN.NS earnings conference call or presentation 11-Feb-21 3:00am GMT - Yahoo Finance


Asia Pacific Anti-Viral Therapies Market To See Tremendous Rise during 2019-2027 wuith Top Companies Like Aurobindo Pharma Ltd, AbbVie, GlaxoSmithKline, AstraZeneca – FLA News - FLA News


Three Weeks Later: A Relook at Aurobindo Pharma - Investing.com India


Covid-19 impact on Europe Active Pharmaceutical Ingredients (API) Market Business Opportunities, Analysis and Overview by 2026 | AbbVie Inc., Astrazeneca, Aurobindo Pharma Ltd., BASF, Bayer AG – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper


Impact of Covid-19 on Europe Active Pharmaceutical Ingredients (Api) Market Is Booming Worldwide | AbbVie Inc., Astrazeneca, Aurobindo Pharma Ltd., BASF, Bayer AG, Boehringer Ingelheim – The Bisouv Network - The Bisouv Network


Erectile Dysfunction Treatment Market to Exhibit a Rise by 6.2% CAGR Between 2019 to 2027 | Mylan Ph - PharmiWeb.com


Covid-19 impact on North America Active Pharmaceutical Ingredients (API) Market Key Vendors, Regional Analysis and Competitive Landscape Forecast by 2026| AbbVie Inc., Astrazeneca, Aurobindo Pharma Ltd., BASF, Bayer AG – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper


BRIEF-Aurobindo Pharma Dec-Quarter Consol Net Profit Jumps - Investing.com India


Cognitive Supplement Market SWOT analysis, Global Profit Growth, Share, Size outlook by 2030 | HVMN Inc., KeyView Labs Inc., Aurobindo Pharma Ltd, Quincy Bioscience - The Courier


Why Aurobindo Pharma’s Shares Ended At A Record High - BloombergQuint


Aurobindo Pharma Shares Fall 6% After U.S. FDA Warning Letter For Subsidiary - BloombergQuint


Aurobindo Pharma Signs Pact To Sell U.S. Unit Natrol For $550 Million - BloombergQuint


Aurobindo Pharma Faces Class Action Suit In U.S. For Hiding Facts - BloombergQuint


Aurobindo Realty set to sail away with AP port EPC deal - BusinessLine


Aurobindo on firm ground but valuations reflect near-term gains - Mint


Aurobindo Pharma Q2 net profit up 26% to ₹805.65 crore - Mint


Aurobindo Pharma Ltd (ARBQY) on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha


Aurobindo Pharma’s unit IV gets a reprieve; focus on new filings - Livemint


Aurobindo Pharma shares hit new high, brokerages see more upside - Mint


Aurobindo Pharma Q4 consolidated profit soars 45% on strong formulation sales - Livemint


Epidural Anesthetic Drugs and Device Market Breaking New Grounds and Touch New Level in upcoming year by| Taj Pharmaceuticals Ltd, Pfizer, Fresenius Kabi – NeighborWebSJ - NeighborWebSJ


Aurobindo Pharma Ltd in demand - Business Standard

Aurobindo Pharma Ltd in demand  Business Standard


Aurobindo remains on firm ground even as valuations reflect near-term gains - Mint


India's pharma industry reevaluating reliance on China APIs - BioWorld Online


Aurobindo Pharma calls off $1 billion deal with Sandoz after failing to get FTC nod - Livemint


Despite political tensions, Aurobindo Pharma bullish on business in China - BusinessLine


Aurobindo Pharma to make COVAXX vaccine for India and UNICEF - WION


Aurobindo Pharma gets USFDA nod for sedative drug - Moneycontrol


Pfizer moves US court against Aurobindo Pharma, Dr Reddy's on cancer drug - Moneycontrol


Aurobindo Pharma’s scrip zooms 8% - BusinessLine


Aurobindo Pharma, promoters settle insider trading case with Sebi - Economic Times


Aurobindo Pharma Advances In Vaccine Race With The Covaxx Deal: Motilal Oswal - BloombergQuint


CSIR, Aurobindo Pharma Collaborate To Develop Covid-19 Vaccine - BloombergQuint


Aurobindo Pharma, Sun Pharma, Lupin Named In Lawsuit In The U.S. - BloombergQuint


Aurobindo Pharma Ltd stays supported - Business Standard


Buy Aurobindo Pharma, target price Rs 1000: Emkay Global - Economic Times


Stock market update: Pharma stocks mixed; Aurobindo Pharma rises 1% - Economic Times


Aurobindo Pharma Ltd completes acquisition of 100% ownership of Eugia Pharma Specialities - Equity Bulls


Aurobindo Pharma Q2 net up 26% at ₹806 crore - BusinessLine


Aurobindo Pharma sued in US for hiding facts on cancer-causing agent - Business Today


Aurobindo Pharma appoints director - Business Standard

Aurobindo Pharma appoints director  Business Standard


Aurobindo Pharma to acquire 100% stake in MViyeS Pharma Ventures - Business Standard


Buy Aurobindo Pharma, target price Rs 985: Motilal Oswal - Economic Times


Aurobindo Pharma: Low Growth, High Valuation for Now - Moneylife


Global Erectile Dysfunction Treatment Market Industry Trends, Growth, Challenges, Share, Demand by Forecasts | Novartis International AG, Torrent Pharmaceuticals Ltd, Pfizer Inc, Bayer Pharma AG – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper


Aurobindo Pharma gets US FDA inspection report for Pashamylaram unit - Livemint


Aurobindo Pharma gathers pace, but new launches in US remain key - Livemint


Aurobindo, Glenmark, Lupin, Sun among 26 firms facing lawsuit in US - Livemint


Teva moves US court against Aurobindo Pharma on cancer drug Bendeka - BusinessLine


Aurobindo Pharma to invest Rs 1,500 cr in Andhra Pradesh - BusinessLine


Aurobindo Pharma Signs Pact To Sell US Unit Natrol - Techstory - Techstory


Aurobindo Pharma enters Covid-19 vaccine race - BusinessLine


Trending stocks: Aurobindo Pharma shares up nearly 2% - Economic Times


Will Aurobindo Pharma Be Able To Find A Cure For Its U.S. FDA Problems? - BloombergQuint


Stock market update: Nifty Pharma index climbs 3%; Aurobindo Pharma jumps 6% - Economic Times


Aurobindo’s US outlook improves but earnings may just be steady - Mint


Buy Aurobindo Pharma, target price Rs 1055: Motilal Oswal - Economic Times


Aurobindo Pharma receives US FDA approval - Angel Broking - Equity Bulls


Aurobindo Pharma Ltd sees good buying - Business Standard


Aurobindo Pharma weathers scrapping of Sandoz deal - BusinessLine


Buy Aurobindo Pharma, target price Rs 880: Motilal Oswal - Economic Times


Aurobindo Pharma plunges over 15% as FDA reopens probe - Economic Times


Aurobindo Pharma Ltd to increase stake in JV company Eugia Pharma Specialities Limited to 100% - Equity Bulls


Buy Aurobindo Pharma, target price Rs 1005: ICICI Securities - Economic Times


Board of Aurobindo Pharma approves transfer of biosimilar business to subsidiary - Business Standard


Aurobindo Pharma Shares Drop Most In 11 Years On U.S. FDA Observations - BloombergQuint


Buy Aurobindo Pharma, target price Rs 745: Motilal Oswal - Economic Times


Aurobindo could face pressure after USFDA action on a plant - Economic Times


Aurobindo Pharma Q3 Review - Progress On New Ventures Continues: ICICI Direct - BloombergQuint


Aurobindo Pharma Ltd board approves 2nd interim dividend of Rs. 1.25 - Equity Bulls


Impact of COVID-19 on Parasomnia Treatment Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | Alpa Laboratories Ltd., Intas Pharmaceutical Ltd., Anuja Healthcare Limited, Lupin Limited, Sandoz International GmbH - NeighborWebSJ


Aurobindo Pharma Pact: CSIR-Centre Developing Proof Of Concept For Covid-19 Vaccine - BloombergQuint


Aurobindo Pharma to launch 40 new products - BusinessLine


Aurobindo Pharma staff donate ₹3 crore to HKMCF - The Hindu


Stock market update: Pharma stocks advance; Aurobindo Pharma rises over 1% - Economic Times


AuroLife Pharma LLC receives warning letter from USFDA for Dayton, New Jersey facility - Equity Bulls


Buy Aurobindo Pharma, target price Rs 527: Nirmal Bang - Economic Times


Aurobindo Pharma gets US FDA voluntary action notice for Hyderabad unit-VIII - Livemint


Aurobindo Pharma Derivatives Strategy - Covered Call - ICICI Securities - Equity Bulls


Healthcare CMO Market 2024: Industry Analysis, Outlook and Forecast Research Report: Top Key Players are Catalent Pharma Solution, Recipharm, Auribindo Pharma Ltd. And Boehringer Ingelheim - Express Keeper


Stock market update: Nifty Pharma index down 1%; Aurobindo Pharma sheds nearly 3% - Economic Times


Aurobindo Pharma falls over 20% on receiving USFDA observations - BusinessLine


Brokerages are Upbeat on Aurobindo Pharma, Average Target of Rs 990 - Investing.com India


Aurobindo Pharma - Approval for 3 products under PLI Scheme - ICICI Securities - Equity Bulls


Buy Aurobindo Pharma, target price Rs 770: ICICI Direct - Economic Times


Buy Aurobindo Pharma, target price Rs 560: Suruchi Kapoor - Economic Times


Aurobindo Pharma Shares Down 6% After Unit 12 Gets Form 483 with Six Observations - News18


Erectile Dysfunction Treatment Market Breakdown, Development and New Market Opportunities & Forecasts | Novartis International AG, Torrent Pharmaceuticals Ltd, Pfizer Inc, Bayer Pharma AG - NeighborWebSJ


Buy Aurobindo Pharma, target price Rs 790: HDFC Securities - Economic Times


Aurobindo Pharma Ltd unit gets 14 observations - Deccan Chronicle


Company Details

CIN.

L24239TG1986PLC015190

ROC Code

RoC-Hyderabad

Date of Incorporation

26/12/1986

D&B D-U-N-S® Number

65-XXX-2092


Company Category

Company limited by Shares

Company SubCategory

Non-govt company

Class of Company

Public

Industry

MANUFACTURING


Authorised Capital( INR)

760,000,000

Paid up Capital( INR)

585,915,609

Number of Members

0

Registered Address

PLOT NO.2,MAITHRIVIHAR,BEHIND MAITHRI VANAM AMEERPET, HYDERABAD ANDHRA PRADESH TG 500038 IN


Email Id

cs@aurobindo.com

Whether Listed or not

Listed

Last AGM

30/08/2018

Last Balance Sheet

31/03/2018


Registration Number

15190

Location

Potentially Related Company Based on Common Directorship

Charges

Charge Holder Name Assets under charge Charge Amount Date of Creation Date of Modification Status
UTI BANK LTD. 250,000,000 06/09/2000 11/02/2005
UTI Bank Limited 500,000,000 14/12/2004 07/03/2005
State Bank of Travancore 500,000,000 10/09/2004 07/03/2005
STATE BANK OF INDIA SAIFABAD(SIB) BRANCH 12,500,000 27/10/1999 24/04/2006
STATE BANK OF INDIA 0 19/01/2006 -
State Bank of India 10,000,000 27/11/2003 23/02/2005
State Bank of India 8,200,000,000 05/06/1997 15/12/2014
STATE BANK OF INDIA 800,000,000 24/10/2007 -
State Bank of Hyderabad 12,750,000,000 29/11/1995 05/01/2015
Standard Chartered Bank 1,640,000,000 29/11/1995 18/02/2014
ING Bank N V 1,856,000,000 28/12/2010 -
IFCI Limited 1,300,000,000 25/05/2012 -
IFCI Limited 1,560,000,000 25/05/2012 -
IFCI Limited 1,645,000,000 28/12/2010 -
IFCI Limited 2,250,000,000 28/12/2010 -
IDBI Bank Limited 2,000,000,000 05/12/2006 14/09/2016
IDBI Bank Limited 430,000,000 03/01/2005 -
ICICI Limited 400,000,000 06/06/2001 01/10/2001
ICICI Bank Limited 2,050,000,000 26/04/2010 19/03/2014
ICICI BANK LIMITED 450,000,000 11/12/1995 01/06/2007
HDFC Bank Ltd 560,000,000 01/04/2000 30/07/2002
HDFC BANK LIMITED 1,640,000,000 16/02/2007 25/08/2014
Export-Import Bank of India 150,000,000 23/12/1999 15/02/2001
Export-Import bank of india 250,000,000 25/09/2001 25/09/2003
Export-Import Bank of India 4,000,000 05/06/2002 27/08/2002
Export-Import Bank of India 4,000,000 17/03/2003 07/07/2003
Export-Import Bank of India 5,000,000 20/12/2003 21/09/2004
Export-Import Bank of India 5,000,000 22/01/2004 -
Export-Import Bank of India 500,000,000 15/09/2004 07/03/2005
Export -Import Bank of India 5,000,000 14/08/2003 21/09/2004
DBS Bank Ltd 1,640,000,000 08/01/2013 20/02/2015
COOPERATIVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A. 871,687,500 28/10/2005 -
CANARA BANK 0 27/09/2003 -
Canara Bank 500,000,000 21/09/2000 29/06/2017
AXIS BANK LIMITED 1,220,000,000 08/12/2005 31/03/2009
Axis Bank Limited 379,750,000 28/02/2011 22/09/2011
ANDHRA BANK 2,000,000,000 01/04/2000 22/06/2017
ANDHRA BANK 2,000,000,000 19/12/2008 02/04/2009
ANDHRA BANK 245,000,000 22/12/2000 31/10/2003
ANDHRA BANK 3,500,000 22/10/2003 -
ALLAHABAD BANK 1,800,000,000 17/08/2007 25/04/2008
A. P. S. F. C. 9,000,000 08/02/2005 -
3i Infotech Trusteeship Services Limited 650,000,000 17/05/2008 10/08/2009

Principals/Signatory Details

Identification Number Principal Names Designation Begin date End date
00050482 GOVINDARAJAN NARAYANAN Managing Director 01/06/2012 12/02/2020
00523576 KANNAN RAGUNATHAN Additional Director 01/06/2012 20/09/2018
01284132 PENAKA VENKATA RAMPRASAD REDDY Director 30/12/1992 -
01284195 KAMBAM NITYANANDA REDDY Wholetime Director 30/12/1992 06/09/2018
01284266 METTU MADAN MOHAN REDDY Wholetime Director 01/01/2013 06/09/2019
01284320 SIVAKUMARAN MEENAKSHISUNDERAM Wholetime Director 01/09/2009 04/10/2019
01316166 AVNIT BIMAL SINGH Director 25/03/2015 -
01628013 PENAKA SARATH CHANDRA REDDY Wholetime Director 27/09/2007 28/02/2020
01694236 SITARAMA MURTHY MANDAVILLI Director 27/09/2007 -
06492679 SAVITA MAHAJAN Director 16/12/2017 -
XXXXXXXXXX ADI REDDY BADDIGAM Company Secretary 01/06/2016 06/11/2019
XXXXXXXXXX SUBRAMANIAN SANTHANAM CFO(KMP) 01/07/2014 06/12/2019

Corporate Family Connections

Detailed profiles of all businesses owned and operated by this company for insights and prospecting.

71 Subsidiaries


0 Branches


4 Affiliates

Company network based on common directorship

© 2021 - Dun & Bradstreet Information Services India Pvt Ltd. All rights reserved.